chidamide + anlotinib

Chidamide + anlotinib is a combination therapy consisting of two small molecule drugs used primarily in oncology clinical trials. Chidamide (also known as tucidinostat) is a selective histone deacetylase (HDAC) inhibitor that modulates gene expression and has demonstrated antitumor activity by inducing cell cycle arrest, apoptosis, and enhancing immune response. Anlotinib is a multi-targeted tyrosine kinase inhibitor that inhibits angiogenesis and tumor cell proliferation by targeting receptors such as VEGFR, FGFR, PDGFR, and c-Kit. The combination aims to leverage the epigenetic modulation of chidamide with the anti-angiogenic and antiproliferative effects of anlotinib for synergistic antitumor efficacy. This regimen has been investigated in phase II clinical studies for advanced or recurrent cancers including pancreatic cancer and HER2-low breast cancer[1][3][7].

Other names

tucidinostat + anlotinib